<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00127985</url>
  </required_header>
  <id_info>
    <org_study_id>NAIF6MPMODS088UNK9071296</org_study_id>
    <nct_id>NCT00127985</nct_id>
  </id_info>
  <brief_title>6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome</brief_title>
  <acronym>NAIF</acronym>
  <official_title>The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Universitario Principe de Asturias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Universitario Principe de Asturias</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Systemic corticosteroids are considered in patients with an adverse clinical&#xD;
      course suffering from conditions like the acute respiratory distress syndrome (ARDS) and&#xD;
      septic shock. Treated patients not only show improved respiratory function, but also&#xD;
      hemodynamic status and overall multiple organ dysfunction score.&#xD;
&#xD;
      Objective: To evaluate the safety and effectiveness of 6-methyl-prednisolone on the clinical&#xD;
      course of multiple organ dysfunction syndrome (MODS).&#xD;
&#xD;
      Design: Multi-center, double-blind, randomized, placebo-controlled.&#xD;
&#xD;
      Intervention: Intravenous administration of 6-methyl-prednisolone or placebo (aqueous&#xD;
      solution). The duration of the study medication administration protocol is 32 days (1).&#xD;
&#xD;
      Primary Endpoints:&#xD;
&#xD;
        1. All cause Intensive Care Unit (ICU) and 28-day mortality&#xD;
&#xD;
        2. Organ dysfunction score on days 4, 7, 14, and 28 of the protocol.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Worldwide intensive care physicians consider administering systemic corticosteroids in&#xD;
      patients with an adverse clinical course suffering from conditions like the acute respiratory&#xD;
      distress syndrome (ARDS) and septic shock. Data from recent small studies performed in&#xD;
      patients with unresolving ARDS (1;2) suggest survival benefits associated with rescue therapy&#xD;
      with relatively prolonged courses of corticosteroids. Treated patients not only show improved&#xD;
      respiratory function, but also hemodynamic status and overall multiple organ dysfunction&#xD;
      score. It has been suggested that that the integrity of the hypothalamic-pituitary-adrenal&#xD;
      axis may be impaired in this patient subset (3;4)&#xD;
&#xD;
      Objective(s):&#xD;
&#xD;
      To evaluate the safety and effectiveness of a non-selective anti-inflammatory strategy, i.e.&#xD;
      6-methyl-prednisolone, on persistent and unresolving inflammatory states, i.e. multiple organ&#xD;
      dysfunction syndrome, on the degree of organ dysfunction and mortality.&#xD;
&#xD;
      Design:&#xD;
&#xD;
      Multi-center, double-blind, randomized, placebo-controlled. Randomization and data entry is&#xD;
      internet based (htpp://www.webnaif.com). Patients will be randomized through a&#xD;
      computer-generated random-number table and stratified by center in blocs of 6. Sample size,&#xD;
      by group 120 patients. The study is powered to detect a 20% reduction in mortality, from 50%&#xD;
      to 30% in 100 patients per study group at the 5% significance level with a power of 80%. An&#xD;
      additional 20% (n=20) per group have been planned to compensate for losses.&#xD;
&#xD;
      Main Inclusion Criteria:&#xD;
&#xD;
        -  Patients with established, unresolving, refractory MODS, in whom all reversible and&#xD;
           treatable causes of persistent MODS have been treated or ruled out.&#xD;
&#xD;
        -  Patients under endotracheal intubation and mechanical ventilation for at least 7 days.&#xD;
&#xD;
        -  Aggregate Multiple Organ Dysfunction Score (5) of greater than 8 over the first seven&#xD;
           days of mechanical ventilation and greater than 5 on the day of inclusion.&#xD;
&#xD;
        -  Written informed consent to participate in the trial signed by next of kin or other&#xD;
           authorized person.&#xD;
&#xD;
      Additional Inclusion Criteria:&#xD;
&#xD;
        -  Main cause or disease at admission: Adequate &quot;source control&quot; is required and refers to&#xD;
           optimal, complete, and definitive surgical and/or medical therapy.&#xD;
&#xD;
        -  Infections:&#xD;
&#xD;
             1. Infectious causes of persistence of MODS have reasonably been ruled out on clinical&#xD;
                or other grounds (infectious endocarditis, undrained abscesses like sinusitis,&#xD;
                empyema or abdominal pus). Consider sampling for culture of broncho-alveolar lavage&#xD;
                fluid, protected specimen brush or other (empyema fluid, lung tissue) in order to&#xD;
                rule out respiratory infection, as well as intra-vascular catheter change and&#xD;
                culture.&#xD;
&#xD;
             2. Present or previous infections, either documented or strongly suspected, have been&#xD;
                treated for at least 3 days before inclusion.&#xD;
&#xD;
        -  Supportive Care: Optimal hemodynamic, renal, hematologic, nutritional &quot;supportive care&quot;&#xD;
           is provided.&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
        -  Decision not to provide full support.&#xD;
&#xD;
        -  Immune status and steroid therapy.&#xD;
&#xD;
             1. Steroid therapy&#xD;
&#xD;
                  -  Currently indicated for chronic or concurrent disease (meningitis, auto-immune&#xD;
                     disease, asthma, acute exacerbation of COPD, or other). Inhaled steroids are&#xD;
                     allowed.&#xD;
&#xD;
                  -  Administered during current admission (&gt; 20 mg/day of 6-methyl-prednisolone or&#xD;
                     equivalent for &gt;48 hours).&#xD;
&#xD;
                  -  Chronic steroid therapy prior to current admission (&gt; 20 mg of&#xD;
                     6-methyl-prednisolone or equivalent/day for &gt; 1 month during previous 3&#xD;
                     months).&#xD;
&#xD;
             2. Other immune-suppressive therapy within the previous 6 months.&#xD;
&#xD;
             3. Known AIDS.&#xD;
&#xD;
             4. Neutropenia &lt; 500/mcl.&#xD;
&#xD;
             5. Preceding organ transplantation.&#xD;
&#xD;
        -  Irreversible and or ultimately fatal clinical conditions like metastatic malignant&#xD;
           disease or cardiogenic shock caused by coronary artery disease.&#xD;
&#xD;
        -  Presence of invasive fungal infection&#xD;
&#xD;
        -  Other significant pre-existing underlying chronic diseases:&#xD;
&#xD;
             1. Severe parenchymal liver disease (Child-Pugh grade C)&#xD;
&#xD;
             2. Severe and irreversible acute or chronic central nervous system disease.&#xD;
&#xD;
             3. Severe end-stage chronic obstructive pulmonary disease (home oxygen or more than 1&#xD;
                exacerbation in previous year)&#xD;
&#xD;
             4. End-stage renal disease (Chronic dialysis).&#xD;
&#xD;
        -  Age less than 18 years.&#xD;
&#xD;
        -  Pregnancy.&#xD;
&#xD;
        -  Morbid obesity: body mass index above 40.&#xD;
&#xD;
        -  Recent (last 3 months) upper GI hemorrhage.&#xD;
&#xD;
        -  Extensive burns (&gt;30% BSA)&#xD;
&#xD;
        -  Known allergy to steroids.&#xD;
&#xD;
        -  Written informed consent not available.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      Intravenous administration of 6-methyl-prednisolone or placebo(aqueous solution). The&#xD;
      duration of the study medication administration protocol is 32 days (1):&#xD;
&#xD;
        -  Initial iv loading dose of 160 mg.&#xD;
&#xD;
        -  An iv bolus injection of 6-methyl-prednisolone is administered every 6 hours:&#xD;
&#xD;
             1. 40 mg on days 1 to 14,&#xD;
&#xD;
             2. 20 mg on days 15 to 21,&#xD;
&#xD;
             3. 10 mg on days 22 to 28,&#xD;
&#xD;
             4. 5 mg on days 29 and 30, and&#xD;
&#xD;
             5. 2.5 mg on days 31 and 32.&#xD;
&#xD;
      Informed consent form and information sheet have been reviewed and approved by the regional&#xD;
      Ethics Committee of Madrid (10 centres), the local review boards of the other participating&#xD;
      centres, and the Agencia Española del Medicamento (Spanish Ministry of Health).&#xD;
&#xD;
      Ethical Approval:&#xD;
&#xD;
      The study protocol has been approved by the regional Ethics Committee of Madrid (10 centres),&#xD;
      the local review boards of the other participating centres, and the Agencia Española del&#xD;
      Medicamento (Spanish Ministry of Health).&#xD;
&#xD;
      Stopping Rules:&#xD;
&#xD;
      The independent Data Monitoring Committee (DMC) will have real-time access to the main&#xD;
      variable &quot;28-day mortality&quot; (and allocation to study group &quot;A&quot; or &quot;B&quot;) and will propose&#xD;
      premature interruption of the trial based on sequential analysis if significant differences&#xD;
      become apparent. The DMC will perform 5 interim analysis, one every 48 included patients and&#xD;
      the criterium used will be a statistically significant difference at the level of p &lt; 0,01&#xD;
      (S.J. Pocock. Clinical Trials. A practical Approach. John Wiley &amp; Sons. New York. 1994).&#xD;
&#xD;
      Primary Endpoints:&#xD;
&#xD;
        1. All cause ICU and 28-day mortality&#xD;
&#xD;
        2. Organ dysfunction score on days 4, 7, 14, and 28 of the protocol.&#xD;
&#xD;
      Planned Subgroup Analysis:&#xD;
&#xD;
      No subgroup analysis are planned.&#xD;
&#xD;
      Side-effects Quantification:&#xD;
&#xD;
      The investigators will use the NIH Toxicity Form with a scale from 1 to 5. Severe adverse&#xD;
      events in this severely ill population are precisely defined and require immediate (less than&#xD;
      24 hours) communication to the study website. The DMC will have access to the variables that&#xD;
      define and describe the SAEs.&#xD;
&#xD;
      Analysis Plan:&#xD;
&#xD;
      Main comparisons are 28-day and ICU mortality between study groups (chi square test for&#xD;
      percentages and log-rank test Kaplan-Meier survival curves. Multiple organ dysfunction score&#xD;
      and Sequential Organ Failure Assessment score will be compared at baseline and on days 4, 7,&#xD;
      14 and 28 (Student's t test and/or non-parametric tests). Independent risk factors for&#xD;
      mortality will be studied by multivariate analysis (Cox regression) of significant&#xD;
      comparisons of the univariate analysis. Analysis sample according to the principle of&#xD;
      intention to treat.&#xD;
&#xD;
      Finishing Date:&#xD;
&#xD;
      The finishing date is 18 months after the first inclusion at each centre. Scheduled beginning&#xD;
      of the trial is August 2005&#xD;
&#xD;
      Reporting Date:&#xD;
&#xD;
      First trimester 2007.&#xD;
&#xD;
      A large study like the present trial is required to obtain definitive data about safety and&#xD;
      effectiveness of 6-methyl-prednisolone administered as rescue therapy in patients with the&#xD;
      multiple organ dysfunction syndrome.&#xD;
&#xD;
      Reference List&#xD;
&#xD;
        1. Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T et al. Effect of&#xD;
           prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome:&#xD;
           a randomized controlled trial. JAMA 1998;280(2):159-65.&#xD;
&#xD;
        2. Biffl WL, Moore FA, Moore EE, Haenel JB, McIntyre RC, Jr., Burch JM. Are corticosteroids&#xD;
           salvage therapy for refractory acute respiratory distress syndrome? Am.J.Surg.&#xD;
           1995;170(6):591-5.&#xD;
&#xD;
        3. Marik PE, Zaloga GP. Adrenal insufficiency during septic shock. Crit Care Med.&#xD;
           2003;31(1):141-5.&#xD;
&#xD;
        4. Loisa P, Rinne T, Kaukinen S. Adrenocortical function and multiple organ failure in&#xD;
           severe sepsis. Acta Anaesthesiol.Scand. 2002;46(2):145-51.&#xD;
&#xD;
        5. Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ&#xD;
           dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med.&#xD;
           1995;23(10):1638-52.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2005</start_date>
  <completion_date type="Anticipated">July 2008</completion_date>
  <primary_completion_date type="Anticipated">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All cause ICU and 28-day mortality</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Organ dysfunction score on days 4, 7, 14, and 28 of the protocol</measure>
    <time_frame>Days 4, 7, 14, and 28.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity: Duration of mechanical ventilation and endotracheal intubation (also a surrogate for acute steroid myopathy)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU-stay</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of steroid therapy</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infections acquired during the protocol</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other complications (hyperglycemia, GI bleeding, acute myopathy, pneumothorax)</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adrenal reserve as evaluated by adrenocorticotropic hormone (ACTH) test.</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Multiple Organ Dysfunction Syndrome</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV 6-methyl-prednisolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>IV Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>6-methyl-prednisolone</intervention_name>
    <description>iv, 2 mg/kg/day, qid</description>
    <arm_group_label>Active</arm_group_label>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Main Inclusion Criteria:&#xD;
&#xD;
        Patients with established, unresolving, refractory MODS, in whom all reversible and&#xD;
        treatable causes of persistent MODS have been treated or ruled out:&#xD;
&#xD;
          -  Patients under endotracheal intubation and mechanical ventilation for at least 7 days.&#xD;
&#xD;
          -  Aggregate Multiple Organ Dysfunction Score (5) of greater than 8 over the first seven&#xD;
             days of mechanical ventilation and greater than 5 on the day of inclusion.&#xD;
&#xD;
          -  Written informed consent to participate in the trial signed by next of kin or other&#xD;
             authorized person.&#xD;
&#xD;
        Additional Inclusion Criteria:&#xD;
&#xD;
          -  Main cause or disease at admission: Adequate &quot;source control&quot; is required and refers&#xD;
             to optimal, complete, and definitive surgical and/or medical therapy.&#xD;
&#xD;
          -  Infections:&#xD;
&#xD;
               1. Infectious causes of persistence of MODS have reasonably been ruled out on&#xD;
                  clinical or other grounds (infectious endocarditis, undrained abscesses like&#xD;
                  sinusitis, empyema or abdominal pus). Consider sampling for culture of&#xD;
                  broncho-alveolar lavage fluid, protected specimen brush or other (empyema fluid,&#xD;
                  lung tissue) in order to rule out respiratory infection, as well as&#xD;
                  intra-vascular catheter change and culture.&#xD;
&#xD;
               2. Present or previous infections, either documented or strongly suspected, have&#xD;
                  been treated for at least 3 days before inclusion.&#xD;
&#xD;
          -  Supportive Care: Optimal hemodynamic, renal, hematologic, nutritional &quot;supportive&#xD;
             care&quot; is provided.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Decision not to provide full support.&#xD;
&#xD;
          -  Immune status and steroid therapy.&#xD;
&#xD;
               1. Steroid therapy&#xD;
&#xD;
                    -  Currently indicated for chronic or concurrent disease (meningitis,&#xD;
                       auto-immune disease, asthma, acute exacerbation of chronic obstructive&#xD;
                       pulmonary disease [COPD], or other). Inhaled steroids are allowed.&#xD;
&#xD;
                    -  Administered during current admission (&gt; 20 mg/day of 6-methyl-prednisolone&#xD;
                       or equivalent for &gt;48 hours).&#xD;
&#xD;
                    -  Chronic steroid therapy prior to current admission (&gt; 20 mg of&#xD;
                       6-methyl-prednisolone or equivalent/day for &gt; 1 month during previous 3&#xD;
                       months).&#xD;
&#xD;
               2. Other immune-suppressive therapy within the previous 6 months.&#xD;
&#xD;
               3. Known AIDS.&#xD;
&#xD;
               4. Neutropenia &lt; 500/mcl.&#xD;
&#xD;
               5. Preceding organ transplantation.&#xD;
&#xD;
          -  Irreversible and or ultimately fatal clinical conditions like metastatic malignant&#xD;
             disease or cardiogenic shock caused by coronary artery disease.&#xD;
&#xD;
          -  Presence of invasive fungal infection&#xD;
&#xD;
          -  Other significant pre-existing underlying chronic diseases:&#xD;
&#xD;
               1. Severe parenchymal liver disease (Child-Pugh grade C)&#xD;
&#xD;
               2. Severe and irreversible acute or chronic central nervous system disease.&#xD;
&#xD;
               3. Severe end-stage chronic obstructive pulmonary disease (home oxygen or more than&#xD;
                  1 exacerbation in previous year)&#xD;
&#xD;
               4. End-stage renal disease (Chronic dialysis).&#xD;
&#xD;
          -  Age less than 18 years.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Morbid obesity: body mass index above 40.&#xD;
&#xD;
          -  Recent (last 3 months) upper gastrointestinal [GI] hemorrhage.&#xD;
&#xD;
          -  Extensive burns (&gt;30% body surface area [BSA])&#xD;
&#xD;
          -  Known allergy to steroids.&#xD;
&#xD;
          -  Written informed consent not available.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miguel Sanchez, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hosp. Univ. Principe de Asturias</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Miguel Sanchez, MD, PhD</last_name>
    <phone>34-91-887-8100</phone>
    <phone_ext>2205</phone_ext>
    <email>miguelsanchez.areachip@wanadoo.es</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Principe de Asturias</name>
      <address>
        <city>Alcala de Henares</city>
        <state>Madrid</state>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raul De Pablo</last_name>
      <phone>34-91-8871-8100</phone>
      <phone_ext>2205</phone_ext>
      <email>rdepablosanchez@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Raul De Pablo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antoni Torres, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Antoni Torres, MD, PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Juan Ramón Badía, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de la Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Reyes, MD., PhD.</last_name>
      <phone>34-91-520-2200</phone>
      <email>Areyes.hlpr@salud.madrid.org</email>
    </contact>
    <contact_backup>
      <last_name>Fernando Lopez, MD., PhD.</last_name>
      <phone>34-91-520-2200</phone>
      <email>fld@inicia.es</email>
    </contact_backup>
    <investigator>
      <last_name>Antonio Reyes, MD., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fernando - Lopez, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Francisco Ortuño Anderiz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francisco - Ortuño Anderiz, MD</last_name>
      <phone>34-91-330-3223</phone>
      <email>portunoa@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Fernando - Martinez Sagasti, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinica Moncloa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Alvarez, MD, PhD.</last_name>
    </contact>
    <contact_backup>
      <last_name>Juan Jose Oñoro, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Manuel Alvarez, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>María Mar Cruz Acuaroni</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Mar - Cruz Acuaroni, MD</last_name>
      <phone>34-925-26-9237</phone>
      <email>mdelca@sescam.jccm.es</email>
    </contact>
    <contact_backup>
      <last_name>Maria José - Pérez Pedrero, MD</last_name>
      <phone>34-925-26-9237</phone>
    </contact_backup>
    <investigator>
      <last_name>Maria Mar - Cruz Acuaroni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maria Jose - Perez Pedrero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Meduri GU, Headley AS, Golden E, Carson SJ, Umberger RA, Kelso T, Tolley EA. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998 Jul 8;280(2):159-65.</citation>
    <PMID>9669790</PMID>
  </reference>
  <reference>
    <citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995 Oct;23(10):1638-52. Review.</citation>
    <PMID>7587228</PMID>
  </reference>
  <verification_date>May 2008</verification_date>
  <study_first_submitted>August 8, 2005</study_first_submitted>
  <study_first_submitted_qc>August 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 9, 2005</study_first_posted>
  <last_update_submitted>May 12, 2008</last_update_submitted>
  <last_update_submitted_qc>May 12, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 13, 2008</last_update_posted>
  <responsible_party>
    <name_title>Miguel Sanchez Garcia, MD, PhD</name_title>
    <organization>Hospital Principe de Asturias</organization>
  </responsible_party>
  <keyword>multiple organ dysfunction syndrome</keyword>
  <keyword>corticosteroids</keyword>
  <keyword>mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Multiple Organ Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone Acetate</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

